Cargando…

Effects of the multi‐kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia

Recently, several targeted agents have been developed for specific subsets of patients with acute myeloid leukaemia (AML), including midostaurin, the first FDA‐approved FLT3 inhibitor for newly diagnosed patients with FLT3 mutations. However, in the initial Phase I/II clinical trials, some patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Weisberg, Ellen, Meng, Chengcheng, Case, Abigail E., Tiv, Hong L., Gokhale, Prafulla C., Buhrlage, Sara J., Yang, Jing, Liu, Xiaoxi, Wang, Jinhua, Gray, Nathanael, Adamia, Sophia, Sattler, Martin, Stone, Richard, Griffin, James D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7077552/ https://www.ncbi.nlm.nih.gov/pubmed/31967735 http://dx.doi.org/10.1111/jcmm.14927

Ejemplares similares

The combination of FLT3 and SYK kinase inhibitors is toxic to leukaemia cells with CBL mutations
por: Weisberg, Ellen, et al.
Publicado: (2020)

Inhibition of the deubiquitinase USP10 induces degradation of SYK
por: Yang, Jing, et al.
Publicado: (2020)

Spotlight on midostaurin in the treatment of FLT3-mutated acute myeloid leukemia and systemic mastocytosis: design, development, and potential place in therapy
por: Weisberg, Ellen, et al.
Publicado: (2017)

Characterization of midostaurin as a dual inhibitor of FLT3 and SYK and potentiation of FLT3 inhibition against FLT3-ITD-driven leukemia harboring activated SYK kinase
por: Weisberg, Ellen L., et al.
Publicado: (2017)

Repurposing of Kinase Inhibitors for Treatment of COVID-19
por: Weisberg, Ellen, et al.
Publicado: (2020)

European Medicines Agency review of midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukaemia and systemic mastocytosis
por: Tzogani, Kyriaki, et al.
Publicado: (2019)

S124: PHOSPHOPROTEOMICS ACCURATELY PREDICTS RESPONSES TO MIDOSTAURIN PLUS CHEMOTHERAPY IN TWO INDEPENDENT COHORTS OF FLT3 MUTANT-POSITIVE ACUTE MYELOID LEUKAEMIA
por: Dokal, Arran, et al.
Publicado: (2023)

Midostaurin: an emerging treatment for acute myeloid leukemia patients
por: Gallogly, Molly Megan, et al.
Publicado: (2016)

Midostaurin reduces Regulatory T cells markers in Acute Myeloid Leukemia
por: Gutierrez, Lucas, et al.
Publicado: (2018)

Midostaurin In Acute Myeloid Leukemia: An Evidence-Based Review And Patient Selection
por: Abbas, Hussein A, et al.
Publicado: (2019)

Reversible Resistance Induced by FLT3 Inhibition: A Novel Resistance Mechanism in Mutant FLT3-Expressing Cells
por: Weisberg, Ellen, et al.
Publicado: (2011)

Antifungal prophylaxis and novel drugs in acute myeloid leukemia: the midostaurin and posaconazole dilemma
por: Stemler, Jannik, et al.
Publicado: (2020)

Chemotherapy of the Myeloid Leukaemias
por: Stuart, John
Publicado: (1980)

Inhibitors of the Transcription Factor STAT3 Decrease Growth and Induce Immune Response Genes in Models of Malignant Pleural Mesothelioma (MPM)
por: Lapidot, Moshe, et al.
Publicado: (2020)

Cotargeting of XPO1 Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Acute Myeloid Leukemia
por: Brinton, Lindsey T., et al.
Publicado: (2020)

Cost-Effectiveness Of Midostaurin In The Treatment Of Acute Myeloid Leukemia With The FLT3 Mutation In Spain
por: Arenaza, Ainhoa, et al.
Publicado: (2019)

Cost-effectiveness analysis for midostaurin versus standard of care in acute myeloid leukemia in the United Kingdom
por: Tremblay, Gabriel, et al.
Publicado: (2018)

Actin cytoskeleton deregulation confers midostaurin resistance in FLT3-mutant acute myeloid leukemia
por: Garitano-Trojaola, Andoni, et al.
Publicado: (2021)

Midostaurin as the Most Likely Cause of Bilateral Adrenal Masses in a Patient with Acute Myeloid Leukemia
por: Schutte, Tim, et al.
Publicado: (2022)

PB1790: ABCB1 AS A POTENTIAL BENEFICIAL TARGET OF MIDOSTAURIN IN ACUTE MYELOID LEUKEMIA
por: Sucha, S., et al.
Publicado: (2022)

Efficacy and toxicity of midostaurin with idarubicin and cytarabine induction in FLT3-mutated acute myeloid leukemia
por: Lee, Julia S., et al.
Publicado: (2023)

Inhibition of SDF-1-induced migration of oncogene-driven myeloid leukemia by the L-RNA aptamer (Spiegelmer), NOX-A12, and potentiation of tyrosine kinase inhibition
por: Weisberg, Ellen L., et al.
Publicado: (2017)

Acute myeloid leukemia cells require 6-phosphogluconate dehydrogenase for cell growth and NADPH-dependent metabolic reprogramming
por: Bhanot, Haymanti, et al.
Publicado: (2017)

Midostaurin-Related Interstitial Lung Injury in FLT3(+) Acute Myeloid Leukemia Post-Allogeneic Transplant
por: Vaidya, Poorva, et al.
Publicado: (2019)

Isavuconazole Therapy of Disseminated and Encephalic Saprochaete Capitata Infection in an Acute Myeloid Leukemia Patient Treated with Midostaurin
por: Perrone, Salvatore, et al.
Publicado: (2020)

Clinical potential of midostaurin in advanced systemic mastocytosis
por: Chandesris, Marie Olivia, et al.
Publicado: (2017)

Essential role of the histone lysine demethylase KDM4A in the biology of malignant pleural mesothelioma (MPM)
por: Lapidot, Moshe, et al.
Publicado: (2021)

Real-World Efficacy of Midostaurin in Aggressive Systemic Mastocytosis
por: Szudy-Szczyrek, Aneta, et al.
Publicado: (2021)

A Rare Case of Midostaurin-Associated Sweet's Syndrome
por: Yasin, Hesham, et al.
Publicado: (2022)

Midostaurin in addition to intensive chemotherapy in acute myeloid leukemia with t(8;21) and KIT and/or FLT3-ITD mutations: results of the SAL MIDOKIT trial
por: Ruhnke, Leo, et al.
Publicado: (2023)

Megaloblastic Erythropoiesis in a Case of Myeloid Leukaemia during Treatment
por: Stone, Frederick H.
Publicado: (1950)

Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications
por: Döhner, Hartmut, et al.
Publicado: (2022)

PB1829: ARGENTINEAN REAL WORLD EXPERIENCE ON MIDOSTAURIN PLUS INTENSIVE CHEMOTHERAPY VS INTENSIVE CHEMOTHERAPY TO TREAT FLT3 POSITIVE ACUTE MYELOID LEUKEMIA PATIENTS
por: Navickas, A., et al.
Publicado: (2022)

1126. Three Cases of Neutropenic Enterocolitis Following Midostaurin Administration
por: Carroll, Ryan, et al.
Publicado: (2018)

FDA Approval Summary: Midostaurin for the Treatment of Advanced Systemic Mastocytosis
por: Kasamon, Yvette L., et al.
Publicado: (2018)

Acute Myeloid Leukaemia in Its Niche: the Bone Marrow Microenvironment in Acute Myeloid Leukaemia
por: Ladikou, E. E., et al.
Publicado: (2020)

Genomic markers of midostaurin drug sensitivity in FLT3 mutated and FLT3 wild-type acute myeloid leukemia patients
por: Rosenberg, Mara W., et al.
Publicado: (2020)

Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia
por: Maziarz, Richard T., et al.
Publicado: (2020)

Combination of midostaurin and ATRA exerts dose-dependent dual effects on acute myeloid leukemia cells with wild type FLT3
por: Lu, Hao, et al.
Publicado: (2022)

Selective Akt Inhibitors Synergize with Tyrosine Kinase Inhibitors and Effectively Override Stroma-Associated Cytoprotection of Mutant FLT3-Positive AML Cells
por: Weisberg, Ellen, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_500sasqb77fdnmjrhe3okmdld7